Why CRISPR Therapeutics Stock Sank Today
Shares of clinical-stage biotech CRISPR Therapeutics (NASDAQ: CRSP) are down an eye-popping 12% as of 12:05 p.m. EDT Wednesday. The biotech's shares sank in response to a patient death in an early stage study assessing the company's off-the-shelf T-cell therapy, CTX110, in patients with CD19+ B-cell malignancies (blood cancers).
The patient in question was the only one to receive the highest dosage of the experimental cell therapy in the study. Although the patient reportedly exhibited a complete response at day 25 following treatment, he was hospitalized the next day for febrile neutropenia (fever with a low white blood cell count) and short-term memory loss/confusion. Less than four weeks later, the man passed away from additional complications.
Image source: Getty Images.
Source Fool.com
